Jerald Korn - 01 Apr 2022 Form 4 Insider Report for Epizyme, Inc.

Reporting relationship: Chief Operating Officer
Issuer ticker: N/A
Reported as of: 01 Apr 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Apr 2022, 18:48:31 UTC
Prior SEC filing: 21 Mar 2022
Next SEC filing: 16 Aug 2022
Source filing: View source filing
Reporting owner signature: /s/ John Weidenbruch, attorney-in-fact

Key filing fact

Jerald Korn filed Form 4 for Epizyme, Inc. on 04 Apr 2022.

Key facts

This page summarizes Jerald Korn's Form 4 filing for Epizyme, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Apr 2022, 18:48.

Change

Previous filing in this sequence was filed on 21 Mar 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EPZM transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +800,000
Change %
Price: $0.000000
Shares after: 800,000
Date: 01 Apr 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 800,000
Exercise price: $1.14
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This equity award was not granted pursuant to any pre-existing equity incentive plan of Epizyme, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4).

Footnote F2

This option was granted on April 1, 2022 with respect to 800,000 shares of Common Stock of the Company, with 25% vesting on April 1, 2023 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.